Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07570966 | Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Jun 22, 2026 | clinicaltrials |
| NCT04565496 | Phase 2 Study of Neoadjuvant PEMbrolizumab Before Radical PROstatectomy in High-risk Prostate Cancer Patients(PEM-PRO) | withdrawn | Phase 2 | 0 | IRCCS San RaffaeleOTHER | 1 | May 15, 2026 |
| clinicaltrials |
| NCT07025512 | 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 8, 2026 | clinicaltrials |
| NCT06881823 | Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC(NeoPSMA) | withdrawn | Phase 1 / Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Dec 29, 2025 | clinicaltrials |
| NCT06060587 | Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone | withdrawn | Phase 2 | 0 | Northwestern UniversityOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT04910425 | PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer | withdrawn | Phase 2 | 0 | Northwestern UniversityOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT05046782 | Abbreviated Biparametric MRI (RSI + T2WI) for Prostate Cancer Detection: Correlation With Histopathology | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 30, 2025 | clinicaltrials |
| NCT06527690 | Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer(REPRESENTATION) | withdrawn | Phase 2 | 0 | Latin American Cooperative Oncology GroupOTHER | 0 | Sep 29, 2025 | clinicaltrials |
| NCT06528210 | Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer | withdrawn | Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Sep 23, 2025 | clinicaltrials |
| NCT04569461 | Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON)(TALON) | withdrawn | Phase 2 | 0 | Duke UniversityOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT03581500 | Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT05815316 | 18F-PSMA PET/MRI for the Diagnosis of Clinically Significant Prostate Cancer | withdrawn | Phase 2 | 0 | IRCCS San RaffaeleOTHER | 0 | Apr 13, 2025 | clinicaltrials |
| NCT06218667 | A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Oct 31, 2024 | clinicaltrials |
| NCT06329830 | 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer(LUNAAR) | withdrawn | Phase 1 / Phase 2 | 0 | Baptist Health South FloridaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03035357 | Neoadjuvant Listeria or Daratumumab in Prostate Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 3, 2024 | clinicaltrials |
| NCT05445882 | N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04243941 | PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer | withdrawn | Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 0 | Mar 21, 2024 | clinicaltrials |
| NCT05574712 | A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 0 | Mar 18, 2024 | clinicaltrials |
| NCT05034562 | Gallium-68 PSMA-11 PET in Participants With Prostate Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 7, 2024 | clinicaltrials |
| NCT04781374 | Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT04995978 | Insulin Resistance and Androgen Deprivation Therapy | withdrawn | Phase 2 | 0 | St. Louis UniversityOTHER | 1 | Jun 23, 2023 | clinicaltrials |
| NCT00771017 | Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer | withdrawn | Phase 2 | 0 | Eastern Cooperative Oncology GroupNETWORK | 0 | May 25, 2023 | clinicaltrials |
| NCT04483414 | 68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer | withdrawn | Phase 2 | 0 | Dana MathewsOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT05705700 | Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP) | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Feb 27, 2023 | clinicaltrials |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors(MATILDA) | withdrawn | Phase 2 | 0 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 0 | Jan 26, 2023 | clinicaltrials |
| NCT03709550 | Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT05191017 | Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | withdrawn | Phase 1 / Phase 2 | 0 | Nuvation Bio Inc.INDUSTRY | 1 | Aug 5, 2022 | clinicaltrials |
| NCT04331717 | Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer(BASH-PC) | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT03800784 | Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer | withdrawn | Phase 2 / Phase 3 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT04020094 | Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer(AtezoVax) | withdrawn | Phase 2 | 0 | University of UtahOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT01802307 | Focal Therapy for Prostate Cancer | withdrawn | Phase 2 | 0 | University of Maryland, BaltimoreOTHER | 1 | May 11, 2021 | clinicaltrials |
| NCT02497638 | LIpitor and biGuanide to Androgen Delay Trial(LIGAND) | withdrawn | Phase 2 | 0 | University Health Network, TorontoOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT04585932 | Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT03173859 | Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC Patients(AERA) | withdrawn | Phase 2 | 0 | University of AthensOTHER | 0 | Nov 18, 2020 | clinicaltrials |
| NCT01079793 | Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery | withdrawn | Phase 1 / Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT01859689 | Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 0 | Jul 27, 2020 | clinicaltrials |
| NCT04272645 | Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 15, 2020 | clinicaltrials |
| NCT02811809 | Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer | withdrawn | Phase 2 | 0 | The University of Texas Health Science Center, HoustonOTHER | 1 | Feb 27, 2020 | clinicaltrials |
| NCT02538432 | Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors | withdrawn | Phase 2 | 0 | University of Maryland, BaltimoreOTHER | 0 | Nov 4, 2019 | clinicaltrials |
| NCT03147196 | Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | withdrawn | Phase 2 | 0 | Mayo ClinicOTHER | 0 | Jan 22, 2019 | clinicaltrials |
| NCT02252978 | Ciprofloxacin Compared to Placebo in Diagnosing Prostate Cancer in Patients Undergoing Prostate Biopsy | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01188408 | Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | INSYS Therapeutics IncINDUSTRY | 1 | Mar 12, 2018 | clinicaltrials |
| NCT00003534 | Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jan 31, 2018 | clinicaltrials |
| NCT00769990 | Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Dec 13, 2017 | clinicaltrials |
| NCT02793219 | Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | The University of Texas Health Science Center, HoustonOTHER | 1 | Oct 30, 2017 | clinicaltrials |
| NCT02793765 | Docetaxel Followed by Provenge in Metastatic Prostate Cancer | withdrawn | Phase 2 | 0 | The University of Texas Health Science Center, HoustonOTHER | 1 | Oct 30, 2017 | clinicaltrials |
| NCT02810886 | Prospective Evaluation of 68Ga-PSMA PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management(ProsPERo) | withdrawn | Phase 2 | 0 | Jules Bordet InstituteOTHER | 0 | Aug 22, 2017 | clinicaltrials |
| NCT00003622 | Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy | withdrawn | Phase 2 | 0 | James AhlgrenOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT01087580 | Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | Northwestern UniversityOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT00598858 | Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate(2007-5904) | withdrawn | Phase 2 | 0 | John P. FruehaufOTHER | 0 | Dec 8, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Jun 22, 2026source: clinicaltrials